SCHEMBL5496459

SCHEMBL5496459

O=C1COc2ccc(OCc3ccccc3)cc2N1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 12/20 0.61
MAOA P21397 10/20 0.61
PARP1 P09874 3/20 0.60
CREBBP Q92793 1/20 0.55
NR3C2 P08235 1/20 0.53
DRD2 P14416 1/20 0.50
DRD4 P21917 1/20 0.50
DRD3 P35462 1/20 0.50
ALOX5 P09917 1/20 0.50
NPC1 O15118 1/20 0.50
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
NFKB1 P19838 1/20 0.50
GRM5 P41594 1/20 0.50
RAB9A P51151 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL2536819 0.94 PARP1 (0.57) MAOBMAOAPARP1CREBBPNR3C2
SCHEMBL6295489 0.90 MAOB (0.62) MAOBMAOAPARP1CREBBPDRD2
SCHEMBL27956879 0.80 ALDH1A1 (0.74) MAOBALDH1A1
SCHEMBL13932181 0.80 NR3C2 (0.58) MAOBMAOAPARP1NR3C2NPC1
SCHEMBL13932182 0.80 NR3C2 (0.58) MAOBMAOAPARP1NR3C2NPC1
SCHEMBL4178218 0.78 MMP12 (0.52) PARP1NR3C2DRD2DRD4ALDH1A1
SCHEMBL4258386 0.78 PARP1 (0.73) MAOAPARP1NR3C2DRD2DRD4
SCHEMBL4272979 0.78 PARP1 (0.73) MAOAPARP1NR3C2DRD2DRD4
SCHEMBL7270318 0.78 GAA (0.59) PARP1ALDH1A1RAB9A
SCHEMBL7844474 0.77 MMP12 (0.51) PARP1NR3C2DRD2DRD4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951855-B2 Benzoxazinone derivatives for use in the treatment of angiogenesis ASTRAZENECA AB (SE) 2005-10-04 US claimed
US-20040122006-A1 Benzoxazinone derivatives for use in the treatment of angiogenesis ASTRAZENECA AB (SE) 2004-06-24 US claimed
EP-1385835-A1 BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS Astrazeneca AB (SE) 2004-02-04 EP claimed
WO-2002085868-A1 BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS ASTRAZENECA AB (SE) 2002-10-31 WO claimed
EP-1791807-A1 THERAPEUTIC DIPHENYL ETHER LIGANDS Pfizer Products Incorporated (US) 2007-06-06 EP disclosed
WO-2006027684-A1 THERAPEUTIC DIPHENYL ETHER LIGANDS PFIZER PRODUCTS INC. (US) 2006-03-16 WO disclosed
US-20060058361-A1 Therapeutic diphenyl ether ligands PFIZER INC 2006-03-16 US disclosed
US-6951855-B2 Benzoxazinone derivatives for use in the treatment of angiogenesis ASTRAZENECA AB (SE) 2005-10-04 US disclosed
US-20040122006-A1 Benzoxazinone derivatives for use in the treatment of angiogenesis ASTRAZENECA AB (SE) 2004-06-24 US disclosed
EP-1385835-A1 BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS Astrazeneca AB (SE) 2004-02-04 EP disclosed
WO-2002085868-A1 BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS ASTRAZENECA AB (SE) 2002-10-31 WO disclosed
EP-0168729-B1 CYAN DYE-FORMING COUPLERS AND PHOTOGRAPHIC ELEMENTS AND PROCESSES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1989-01-04 EP disclosed
US-4762925-A COLOR PHOTOGRAPHY MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1988-08-09 US disclosed
US-4672013-A 6-HYDROXYL-2H-U,4-BENZOXAZIN-3-(4H)-ONE COUPLER REACTS WITH DEVELOPER TO GIVE INDOANILINE DYE MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1987-06-09 US disclosed
US-4591548-A 6-HYDROXY-2H-1,4-BENZOXAZIN-3(4H)-ONES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1986-05-27 US disclosed
EP-0168729-A2 Cyan dye-forming couplers and photographic elements and processes MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1986-01-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122006-A1 Benzoxazinone derivatives for use in the treatment of angiogenesis HAX1, VEGFA, HYOU1 MAOB 1050/4885MAOA 1737/4885PARP1 2666/4885
US-20060058361-A1 Therapeutic diphenyl ether ligands HTR2B, HTR2C, HTR3B MAOB 35/4885MAOA 94/4885PARP1 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.